BUZZ-DexCom shares rise after raising the lower end of its 2026 revenue forecast range
路透社2026/10/29 22:26October 29 - ** DexCom (DXCM.O) shares rose 2.6% in after-hours trading to $81.97
** The medical device maker expects (link) 2026 revenue to range between $5.20 billion and $5.25 billion, up from the previous forecast range of $5.18 billion to $5.25 billion
** The company reported third-quarter revenue of $1.34 billion, beating analysts’ consensus estimate of $1.327 billion — according to LSEG data
** The company also announced approval of a stock buyback program of up to $1 billion
** As of the previous session’s close, the stock has gained 20.4% year to date
(To facilitate non-native English speakers, Reuters offers automated translations of its reports into several other languages. As automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the translated text and provides it solely for reader convenience. Reuters accepts no responsibility for any damage or loss caused by the use of the automated translation tool.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
South Korea’s current account surplus in September exceeded 60 billions USD for the first time, with semiconductor exports becoming the main driver
Driven by booming semiconductor exports, South Korea's current account surplus in September surged to a record high.
CoreWeave (CRWV.US) bonds hit a new low as changes in Texas data center policies impact AI cloud trading
CoreWeave (CRWV.US) bonds fell sharply on Wednesday, with some dropping to new lows.
AstraZeneca (AZN.US) reportedly receives a $10 billion acquisition offer! Shares of obesity drug developer Rhythm (RYTM.US) soar in response
According to three people familiar with the matter, AstraZeneca previously proposed to acquire obesity drug developer Rhythm Pharmaceuticals for approximately 10 billion dollars.
Goldman Sachs and Apollo in Talks to Sell 40 Billion-Dollar AI Chip Financing for SpaceX (SPCX.US), Market's Willingness to Take Over Faces Test
Goldman Sachs (GS.US) and Apollo Global Management (APO.US) are in talks with Wall Street investors to begin selling portions of a roughly $40 billion chip financing deal for SpaceX (SPCX.US).
Crypto prices
More
